Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBT Margin (2017 - 2025)

Autolus Therapeutics' EBT Margin history spans 6 years, with the latest figure at 376.78% for Q4 2025.

  • For Q4 2025, EBT Margin rose 8977495.0% year-over-year to 376.78%; the TTM value through Dec 2025 reached 378.78%, up 178466.0%, while the annual FY2025 figure was 378.78%, 178657.0% up from the prior year.
  • EBT Margin reached 376.78% in Q4 2025 per AUTL's latest filing, down from 370.79% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 227.12% in Q2 2025 to a low of 90151.72% in Q4 2024.
  • Average EBT Margin over 4 years is 14347.46%, with a median of 756.36% recorded in 2025.
  • The largest YoY upside for EBT Margin was 8977495bps in 2025 against a maximum downside of -23459bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 22342.17% in 2022, then surged by 49bps to 11298.03% in 2023, then plummeted by -698bps to 90151.72% in 2024, then surged by 100bps to 376.78% in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EBT Margin are 376.78% (Q4 2025), 370.79% (Q3 2025), and 227.12% (Q2 2025).